Prognostic Role of PGE2 Receptor EP2 in Esophageal Squamous Cell Carcinoma

Kuang T. Kuo, Hao W. Wang, Teh Ying Chou, Wen H. Hsu, Han Shui Hsu, Chi Hung Lin, Liang Shun Wang

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Prostaglandin E2 (PGE2), a major cyclooxygenase-2 (COX-2) product, has been shown to affect numerous tumorigenic processes. PGE2 acts through G-protein-coupled receptors designated as EPs. Recently it has been documented that PGE2 promotes colon cancer cell growth via EP2. However, the expression and the prognostic role of EP2 in esophageal squamous cell carcinoma (ESCC) remained unknown. From January 1995 to January 2001, tissue samples from 226 patients with ESCC who underwent esophagectomies at our institutions were collected and made into tissue core arrays for study. EP2 expression was examined by immunohistochemical staining and confirmed by Western blot. The clinicopathologic data were then analyzed. EP2 overexpression was observed in 43.4% (98/226) of ESCC. Overexpression of EP2 correlated positively with depth of tumor invasion (T status) (P = 0.016) and was associated with worse overall survival (P = 0.047). In patients without regional or distant lymph node metastasis (N0 or M0), EP2 overexpression was associated with worse overall survival (P = 0.033 and P = 0.003, respectively). Using Cox regression analysis, T status, N status, and M status were the independent factors of overall survival, but EP2 expression was not. However, when focusing on patients with T1-3N0M0 status, EP2 expression became an independent factor of overall survival (P = 0.048). Our results show that EP2 overexpression was associated with worse prognosis, and correlated positively with T status in ESCC. Meanwhile, among those patients at earlier stages, EP2 overexpression significantly disclosed patients at high risks for poor prognosis.

Original languageEnglish
Pages (from-to)352-360
Number of pages9
JournalAnnals of Surgical Oncology
Volume16
Issue number2
DOIs
Publication statusPublished - Feb 2009
Externally publishedYes

Fingerprint

Prostaglandin Receptors
Dinoprostone
Survival
Esophagectomy
Cyclooxygenase 2
G-Protein-Coupled Receptors
Colonic Neoplasms
Lymph Nodes
Western Blotting
Regression Analysis
Esophageal Squamous Cell Carcinoma
Staining and Labeling
Neoplasm Metastasis
Growth
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Kuo, K. T., Wang, H. W., Chou, T. Y., Hsu, W. H., Hsu, H. S., Lin, C. H., & Wang, L. S. (2009). Prognostic Role of PGE2 Receptor EP2 in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 16(2), 352-360. https://doi.org/10.1245/s10434-008-0242-2

Prognostic Role of PGE2 Receptor EP2 in Esophageal Squamous Cell Carcinoma. / Kuo, Kuang T.; Wang, Hao W.; Chou, Teh Ying; Hsu, Wen H.; Hsu, Han Shui; Lin, Chi Hung; Wang, Liang Shun.

In: Annals of Surgical Oncology, Vol. 16, No. 2, 02.2009, p. 352-360.

Research output: Contribution to journalArticle

Kuo, KT, Wang, HW, Chou, TY, Hsu, WH, Hsu, HS, Lin, CH & Wang, LS 2009, 'Prognostic Role of PGE2 Receptor EP2 in Esophageal Squamous Cell Carcinoma', Annals of Surgical Oncology, vol. 16, no. 2, pp. 352-360. https://doi.org/10.1245/s10434-008-0242-2
Kuo, Kuang T. ; Wang, Hao W. ; Chou, Teh Ying ; Hsu, Wen H. ; Hsu, Han Shui ; Lin, Chi Hung ; Wang, Liang Shun. / Prognostic Role of PGE2 Receptor EP2 in Esophageal Squamous Cell Carcinoma. In: Annals of Surgical Oncology. 2009 ; Vol. 16, No. 2. pp. 352-360.
@article{5cbc78dc4f9a4ade94eb81f2a19ca4ae,
title = "Prognostic Role of PGE2 Receptor EP2 in Esophageal Squamous Cell Carcinoma",
abstract = "Prostaglandin E2 (PGE2), a major cyclooxygenase-2 (COX-2) product, has been shown to affect numerous tumorigenic processes. PGE2 acts through G-protein-coupled receptors designated as EPs. Recently it has been documented that PGE2 promotes colon cancer cell growth via EP2. However, the expression and the prognostic role of EP2 in esophageal squamous cell carcinoma (ESCC) remained unknown. From January 1995 to January 2001, tissue samples from 226 patients with ESCC who underwent esophagectomies at our institutions were collected and made into tissue core arrays for study. EP2 expression was examined by immunohistochemical staining and confirmed by Western blot. The clinicopathologic data were then analyzed. EP2 overexpression was observed in 43.4{\%} (98/226) of ESCC. Overexpression of EP2 correlated positively with depth of tumor invasion (T status) (P = 0.016) and was associated with worse overall survival (P = 0.047). In patients without regional or distant lymph node metastasis (N0 or M0), EP2 overexpression was associated with worse overall survival (P = 0.033 and P = 0.003, respectively). Using Cox regression analysis, T status, N status, and M status were the independent factors of overall survival, but EP2 expression was not. However, when focusing on patients with T1-3N0M0 status, EP2 expression became an independent factor of overall survival (P = 0.048). Our results show that EP2 overexpression was associated with worse prognosis, and correlated positively with T status in ESCC. Meanwhile, among those patients at earlier stages, EP2 overexpression significantly disclosed patients at high risks for poor prognosis.",
author = "Kuo, {Kuang T.} and Wang, {Hao W.} and Chou, {Teh Ying} and Hsu, {Wen H.} and Hsu, {Han Shui} and Lin, {Chi Hung} and Wang, {Liang Shun}",
year = "2009",
month = "2",
doi = "10.1245/s10434-008-0242-2",
language = "English",
volume = "16",
pages = "352--360",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Prognostic Role of PGE2 Receptor EP2 in Esophageal Squamous Cell Carcinoma

AU - Kuo, Kuang T.

AU - Wang, Hao W.

AU - Chou, Teh Ying

AU - Hsu, Wen H.

AU - Hsu, Han Shui

AU - Lin, Chi Hung

AU - Wang, Liang Shun

PY - 2009/2

Y1 - 2009/2

N2 - Prostaglandin E2 (PGE2), a major cyclooxygenase-2 (COX-2) product, has been shown to affect numerous tumorigenic processes. PGE2 acts through G-protein-coupled receptors designated as EPs. Recently it has been documented that PGE2 promotes colon cancer cell growth via EP2. However, the expression and the prognostic role of EP2 in esophageal squamous cell carcinoma (ESCC) remained unknown. From January 1995 to January 2001, tissue samples from 226 patients with ESCC who underwent esophagectomies at our institutions were collected and made into tissue core arrays for study. EP2 expression was examined by immunohistochemical staining and confirmed by Western blot. The clinicopathologic data were then analyzed. EP2 overexpression was observed in 43.4% (98/226) of ESCC. Overexpression of EP2 correlated positively with depth of tumor invasion (T status) (P = 0.016) and was associated with worse overall survival (P = 0.047). In patients without regional or distant lymph node metastasis (N0 or M0), EP2 overexpression was associated with worse overall survival (P = 0.033 and P = 0.003, respectively). Using Cox regression analysis, T status, N status, and M status were the independent factors of overall survival, but EP2 expression was not. However, when focusing on patients with T1-3N0M0 status, EP2 expression became an independent factor of overall survival (P = 0.048). Our results show that EP2 overexpression was associated with worse prognosis, and correlated positively with T status in ESCC. Meanwhile, among those patients at earlier stages, EP2 overexpression significantly disclosed patients at high risks for poor prognosis.

AB - Prostaglandin E2 (PGE2), a major cyclooxygenase-2 (COX-2) product, has been shown to affect numerous tumorigenic processes. PGE2 acts through G-protein-coupled receptors designated as EPs. Recently it has been documented that PGE2 promotes colon cancer cell growth via EP2. However, the expression and the prognostic role of EP2 in esophageal squamous cell carcinoma (ESCC) remained unknown. From January 1995 to January 2001, tissue samples from 226 patients with ESCC who underwent esophagectomies at our institutions were collected and made into tissue core arrays for study. EP2 expression was examined by immunohistochemical staining and confirmed by Western blot. The clinicopathologic data were then analyzed. EP2 overexpression was observed in 43.4% (98/226) of ESCC. Overexpression of EP2 correlated positively with depth of tumor invasion (T status) (P = 0.016) and was associated with worse overall survival (P = 0.047). In patients without regional or distant lymph node metastasis (N0 or M0), EP2 overexpression was associated with worse overall survival (P = 0.033 and P = 0.003, respectively). Using Cox regression analysis, T status, N status, and M status were the independent factors of overall survival, but EP2 expression was not. However, when focusing on patients with T1-3N0M0 status, EP2 expression became an independent factor of overall survival (P = 0.048). Our results show that EP2 overexpression was associated with worse prognosis, and correlated positively with T status in ESCC. Meanwhile, among those patients at earlier stages, EP2 overexpression significantly disclosed patients at high risks for poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=59449084521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449084521&partnerID=8YFLogxK

U2 - 10.1245/s10434-008-0242-2

DO - 10.1245/s10434-008-0242-2

M3 - Article

VL - 16

SP - 352

EP - 360

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 2

ER -